-- The FDA has granted Breakthrough Therapy Designation for SkinTE based on key positive data from the Phase II study in Wagner1 DFUs highlighting the ongoing unmet need in this patient population -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results